CanariaBio Announces Joint Clinical Trial with GSK

[Asia Economy Reporter Jang Hyowon] Canary Bio (formerly OQP), a biotech company specializing in immune checkpoint inhibitor development, announced on the 22nd that it will begin joint clinical trials with GSK.

This clinical trial targets platinum-sensitive recurrent ovarian cancer patients and involves the combined administration of Canary Bio's oregovomab and GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, Zejula (niraparib), to verify safety and efficacy.

According to the joint clinical agreement, Canary Bio will lead the clinical trial conducted in the United States, while GSK will supply niraparib free of charge for the clinical research and provide financial support of USD 200,000.

Nahanik, CEO of Canary Bio, stated, "Zejula is the only once-daily oral first-line maintenance drug for ovarian cancer patients," adding, "We believe we have a responsibility to conduct research combining Zejula and oregovomab for ovarian cancer patients."

Oregovomab, Canary Bio's main pipeline, is a mouse monoclonal IgG1 antibody that induces an immune response against CA125, which is overexpressed in ovarian cancer. When oregovomab was administered concurrently with first-line chemotherapy, it demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS), and is currently undergoing global Phase 3 clinical trials.

Meanwhile, GSK's Zejula (niraparib) is a once-daily oral poly (ADP-ribose) polymerase (PARP) inhibitor approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Several pivotal clinical studies are currently underway. GSK is conducting clinical development programs evaluating combination therapies of niraparib with other treatments for ovarian cancer and various other cancer types.

This content was produced with the assistance of AI translation services.